Ipilimumab, an inhibitor of CTLA-4 (anti-CTLA-4), has been approved for the treatment of advanced or unresectable melanoma This agent has been shown to be effective as monotherapy and in combination with nivolumab (anti-PD-1) [60]. This evidence concerns the gene CTLA4 and melanoma.